We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Stock Moves -1.21%: What You Should Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $49.89, moving -1.21% from the previous trading session. The stock's change was equal to S&P 500. Elsewhere, the Dow gained 0.02%, while the tech-heavy Nasdaq lost 2.6%.
Prior to today's trading, shares of the company had lost 9.43% lagged the Medical sector's gain of 2.71% and the S&P 500's loss of 0.03%.
The upcoming earnings release of CRISPR Therapeutics AG will be of great interest to investors. The company is predicted to post an EPS of -$1.07, indicating a 8.55% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $9.95 million, reflecting a 1017.42% rise from the equivalent quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$4.48 per share and revenue of $32.45 million. These totals would mark changes of +30.76% and +824.53%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.22% decrease. Right now, CRISPR Therapeutics AG possesses a Zacks Rank of #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 105, positioning it in the top 43% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Stock Moves -1.21%: What You Should Know
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $49.89, moving -1.21% from the previous trading session. The stock's change was equal to S&P 500. Elsewhere, the Dow gained 0.02%, while the tech-heavy Nasdaq lost 2.6%.
Prior to today's trading, shares of the company had lost 9.43% lagged the Medical sector's gain of 2.71% and the S&P 500's loss of 0.03%.
The upcoming earnings release of CRISPR Therapeutics AG will be of great interest to investors. The company is predicted to post an EPS of -$1.07, indicating a 8.55% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $9.95 million, reflecting a 1017.42% rise from the equivalent quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$4.48 per share and revenue of $32.45 million. These totals would mark changes of +30.76% and +824.53%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.22% decrease. Right now, CRISPR Therapeutics AG possesses a Zacks Rank of #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 105, positioning it in the top 43% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.